Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 6/20 | 0.50 |
| ▸ | BACE1 | P56817 | 5/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | CASP6 | P55212 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL447119 | 0.88 | BACE1 (0.58) | AKR1B1BACE1LMNAHTTHPGD | |
| SCHEMBL30016504 | 0.82 | BACE1 (0.48) | AKR1B1BACE1LMNAHTTHPGD | |
| SCHEMBL24699359 | 0.82 | BACE1 (0.48) | AKR1B1BACE1LMNAHTTHPGD | |
| SCHEMBL2571886 | 0.82 | CASP6 (0.64) | AKR1B1LMNAHTTHPGDCASP6 | |
| SCHEMBL445231 | 0.78 | BACE1 (0.49) | AKR1B1BACE1 | |
| SCHEMBL427841 | 0.77 | BACE1 (0.52) | BACE1 | |
| SCHEMBL1978797 | 0.77 | BACE1 (0.46) | AKR1B1BACE1 | |
| SCHEMBL444596 | 0.76 | CASP6 (0.39) | AKR1B1LMNAHTTHPGDCASP6 | |
| SCHEMBL429148 | 0.76 | HTT (0.40) | AKR1B1LMNAHTTHPGDCASP6 | |
| SCHEMBL448629 | 0.76 | AKR1B1 (0.67) | AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | APP, BACE1, PSEN1 | AKR1B1 112/4885BACE1 2/4885LMNA 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.